Key Highlights

  • Elevance Health (NYSE:ELV) reported third-quarter adjusted EPS of USD 6.99 on Wednesday, October 21, 2026, up 15.9% from USD 6.03 and well above consensus estimates, on revenue of USD 51.4 billion.
  • The benefit expense ratio, the share of premiums paid in medical claims, improved by 70 basis points to 90.6%, against 91.3% a year earlier.
  • The company raised 2026 adjusted EPS guidance to at least USD 29.00 and guided to at least 12% growth in 2027 from a baseline of at least USD 26.75.
  • The result contrasted with Molina Healthcare (NYSE:MOH), whose consolidated medical care ratio rose to 92.9% on the same day, as Medicaid costs pushed its GAAP EPS down 52%.

A Clean Beat in Managed Care

Elevance Health (NYSE:ELV), one of the largest US health insurers and the operator of Anthem plans, reported third-quarter results on Wednesday, October 21, 2026. Adjusted EPS rose 15.9% to USD 6.99, and GAAP EPS rose 17.9% to USD 6.27. Total revenue grew 1.4% to USD 51.4 billion. The benefit expense ratio improved to 90.6% from 91.3%. Medical membership fell 1.1% to 44.9 million. Elevance raised 2026 guidance to at least USD 29.00 in adjusted EPS, at least USD 22.00 in GAAP EPS and at least USD 6.5 billion in operating cash flow. It also guided to adjusted EPS growth of at least 12% in 2027 from a baseline of at least USD 26.75. The company bought back USD 330 million of stock in the quarter.

How Medical Costs and Services Drove the Beat

For Elevance Health (NYSE:ELV), profit growth came from lower claims costs relative to premiums and from its services arms rather than from revenue. A 70 basis point improvement in the benefit expense ratio, on roughly USD 43 billion of Health Benefits segment revenue, is worth about USD 300 million in quarterly margin on simple arithmetic. The Health Benefits segment still earned only a 1.0% margin, down from 1.4%, partly because operating expenses rose to 11.4% of revenue on one-time investments. The services businesses carried more of the load: CarelonRx, the pharmacy benefit manager, lifted operating gain 10.8% to USD 616 million, and Carelon Services grew operating gain 33.3% to USD 292 million. The 2027 baseline of USD 26.75 excludes one-time items, so it sits below the 2026 figure.

Risks and What to Watch

The first risk for Elevance Health (NYSE:ELV) is that cost trend reaccelerates, since a 90.6% benefit expense ratio leaves a thin buffer against higher hospital and drug use. The second is policy: Medicaid eligibility changes, Medicare Advantage rates and subsidies on individual exchange plans could all shift after the midterm elections. The third is membership, which fell by 487,000 year on year and limits premium growth. Pharmacy benefit managers also face regulatory scrutiny of their pricing practices. Investors should watch the Fed decision on Wednesday, October 28, 2026, the midterm elections on Tuesday, November 3, 2026, Medicare enrolment closing on Monday, December 7 and the dividend of USD 1.72 payable on Friday, December 18.

Where Things Stand

The answer is that Elevance Health (NYSE:ELV) lifted its EPS floor to USD 29 because claims costs improved by 70 basis points and its Carelon businesses grew profit faster than insurance. That stands in contrast with Molina, where Medicaid costs worsened. The 2027 guide of at least 12% growth from USD 26.75 sets the next bar. The next catalysts are the Fed decision on October 28, the midterm elections on November 3 and enrolment results for 2027. Guidance is a forecast, not a guarantee, and this is not investment advice.